Review reveals SNAI2 drives endothelial transition and tissue remodeling across cardiovascular diseases, highlighting its promise as a diagnostic biomarker and therapeutic target.
Snail family transcriptional repressor 2 (SNAI2), also known as SLUG, is a canonical driver of epithelial-mesenchymal transition (EMT). While its oncogenic roles are well-established, emerging evidence underscores its pivotal involvement in cardiovascular diseases (CVDs). This review systematically summarizes the multifaceted functions of SNAI2 in the cardiovascular system, highlighting its role in mediating endothelial-to-mesenchymal transition (EndMT) and vascular smooth muscle cell (VSMC) phenotypic reprogramming. We detail the involvement of SNAI2 across a spectrum of pathologies, including atherosclerosis, aortic aneurysm, valvular heart disease, myocardial fibrosis, and pulmonary arterial hypertension. By acting as a critical nexus in signaling networks such as TGF-β, Notch, and Wnt, SNAI2 regulates cellular fate and extracellular matrix remodeling under pathological stress. Finally, we discuss the potential of SNAI2 as a diagnostic biomarker and a novel therapeutic target, offering prospective insights for the clinical management of CVDs.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: